Affimed N.V. (NASDAQ:AFMD) is set to announce third quarter earning results on Tuesday 10th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, AFMD to report 3Q20 loss of $ 0.1 per share.
For the full year, analysts anticipate top line of $ 26.62 million, while looking forward to loss of $ 0.52 per share bottom line.
Previous Quarter Performance
Affimed N.V. unfold loss for the second quarter of $ 0.18 per share, from the revenue of $ 3.23 million. The quarterly revenues declined 26.92 percent compared with the same quarter last year. According to street consensus, AFMD was expected to report 2Q20 loss of $ 0.16 per share from revenue of $ 5.52 million. The bottom line results missed street analysts by $ 0.02 or 12.5 percent, at the same time, top line results fell short of analysts by $ 2.29 million or 41.49 percent.
Stock Performance
Shares of Affimed N.V. traded up $ 0.31 or 9.06 percent on Monday, reaching $ 3.73 with volume of 1.09 million shares. Affimed N.V. has traded high as $ 3.80 and has cracked $ 3.47 on the downward trend
According to the previous trading day, closing price of $ 3.73, representing a 140.85 % increase from the 52 week low of $ 1.42 and a 30.35 % decrease over the 52 week high of $ 4.91.
The company has a market capital of $ 315.16 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Affimed N.V. will be hosting a conference call at 8:30 AM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.affimed.com
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The companys products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.
